Abstract: The present invention relates to uses of and methods of using activators of Nrf2 to enhance natural killer (NK) cell and/or T cell activity and/or survival, particularly in response to stress. The NK cells and/or T cells can be utilised in the treatment of cancer via enhanced cell therapy.

Abstract: The present invention provides an in vitro method for the manufacture of a dendritic cell (DC) cancer vaccine, said method comprising the steps of: (i) providing a plurality of phagocytosable particles, wherein each phagocytosable particle comprises a core and an antigenic construct tightly associated to the core, wherein the antigenic construct comprises at least one epitope peptide having an amino acid sequence corresponding to an amino acid sequence of a part of a protein or peptide known or suspected to be expressed by a cancer cell in a subject; (ii) providing a sample of DCs; and (iii) contacting the sample of DCs with the plurality of phagocytosable particles in vitro and under conditions allowing for the phagocytosis of at least one phagocytosable particle by a DC. The present invention also provides a DC cancer vaccine produced by the method of the invention, and the use a DC cancer vaccine of the invention as a medicament and for the ex vivo expansion of anticancer T-cells.

Abstract: The disclosure relates, in some aspects, to methods and compositions for production of immunomodulatory compositions. In some embodiments, the disclosure provides host cells which have been treated ex vivo with one or more oligonucleotide agents capable of controlling and/or reducing the differentiation of the host cell. In some embodiments, compositions and methods described by the disclosure are useful as immunogenic modulators for treating cancer.

Abstract: The present invention relates to cell culture in bioreactors, such as flexible cellbag bioreactors. More specifically the present invention relates to methods for simplifying the production of clinically relevant cell products for use in cell therapy.

Abstract: The present invention relates to cell culture in bioreactors, such as flexible cellbag bioreactors. More specifically the present invention relates to methods for simplifying the production of clinically relevant cell products for use in cell therapy.

Abstract: An object of the invention is to provide a vaccine adjuvant that is comprised of a vector capable of expressing a polynucleotide binding protein in excess of levels already present in cells. Expression of the polynucleotide binding protein initiates intracellular pathways that lead to expression of type 1 interferons. In concert with expression of type 1 interferons, other cytokines are expressed, and the immune response to vaccine antigens given with the adjuvant is enhanced.

Abstract: A vaccine for preventing formation of blood vessels, for example neoangiogenesis, as well as repressing existing vascularization associated with tumors and other diseases, comprising angiomotin, for example as a whole molecule or fragment thereof or encoded as a gene or mRNA, or administered as dendritic cells (DC cells) expressing angiomotin, which may be utilized to generate immune responses to the angiomotin molecule. Inhibition of angiogenesis and delay in tumor outgrowth in animal models of cancer is achieved.

Abstract: A method of vaccinating a mammal against a disease state, comprising administrating to said mammal, within an appropriate vector, a nucleotide sequence encoding an antigenic peptide associated with the disease state; additionally administering to said mammal a compound which enhances both humoral and cellular immune responses initiated by the antigenic peptide, the compound being selected from the list contained herein, wherein the compound is preferably Tucaresol or a physiologically acceptable salt or ester thereof, where appropriate.

Abstract: An apparatus for safely emptying aerosol spray cans filled with active ingredient and flammable propellant gas which cans have valve seat inserts for spraying the active ingredient is provided. The apparatus comprises an explosion-proof casing (1) with a cap (3), a discharge pipe (7) connected to the lower end of casing (1), a first valve (12) for venting the gaseous propellant and which shuts off discharge pipe (7), a second valve (13) for draining off the liquid active ingredient which shuts off discharge pipe (7) and clamp means (5) sealed in explosion-proof manner passing through the base of casing (1) and which is movable upwardly and downwardly for removing the valve seat from a spray can placed in casing (1).